Holen Sie sich die Stockscreener-App
61.97
3.16%
-2.02
Handel nachbörslich:
61.97
Schlusskurs vom Vortag:
$63.99
Offen:
$63.02
24-Stunden-Volumen:
1.92M
Relative Volume:
0.77
Marktkapitalisierung:
$5.64B
Einnahmen:
$170.10M
Nettoeinkommen (Verlust:
$-239.59M
KGV:
-22.13
EPS:
-2.8
Netto-Cashflow:
$-191.20M
1W Leistung:
-5.71%
1M Leistung:
-8.52%
6M Leistung:
+62.01%
1J Leistung:
+22.08%
1-Tages-Spanne:
$60.53
$64.74
1-Wochen-Bereich:
$60.53
$65.98
52-Wochen-Spanne:
$30.04
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Firmenname
Crispr Therapeutics Ag
Sektor
Branche
Telefon
(617) 315-4600
Adresse
BAARERSTRASSE 14, ZUG
Vergleichen Sie CRSP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
61.97 | 5.82B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | JP Morgan | Overweight |
| 2025-02-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Hochstufung | TD Cowen | Sell → Hold |
| 2025-02-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-08-02 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-28 | Fortgesetzt | Guggenheim | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-11 | Herabstufung | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Eingeleitet | Mizuho | Buy |
| 2023-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-04-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-08-09 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-04-21 | Hochstufung | Jefferies | Hold → Buy |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2020-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-10 | Bestätigt | Needham | Buy |
| 2020-12-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-07-28 | Bestätigt | Needham | Buy |
| 2020-07-14 | Eingeleitet | SunTrust | Buy |
| 2020-06-15 | Bestätigt | Canaccord Genuity | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Eingeleitet | Jefferies | Buy |
| 2019-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-06-10 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-14 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-28 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-22 | Herabstufung | Citigroup | Neutral → Sell |
Alle ansehen
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
Is CRISPR Therapeutics AG showing signs of accumulation2025 Year in Review & Fast Exit and Entry Strategy Plans - newser.com
Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings? - Yahoo! Finance Australia
What to do if you’re stuck in CRISPR Therapeutics AGJuly 2025 Volume & Reliable Price Breakout Alerts - newser.com
Has CRISPR Therapeutics AG found a price floorQuarterly Earnings Summary & Reliable Momentum Entry Alerts - newser.com
CRISPR Therapeutics AG stock trendline breakdownPortfolio Performance Report & High Return Trade Opportunity Guides - newser.com
Why retail investors favor CRISPR Therapeutics AG stock2025 Earnings Surprises & Fast Momentum Entry Tips - newser.com
Why CRISPR Therapeutics AG stock could rally in 2025July 2025 Decliners & Verified Momentum Stock Ideas - newser.com
How to build a dashboard for CRISPR Therapeutics AG stockJuly 2025 Fed Impact & Smart Investment Allocation Tips - newser.com
Visualizing CRISPR Therapeutics AG stock with heatmapsTrade Exit Summary & Free Safe Entry Trade Signal Reports - newser.com
Can CRISPR Therapeutics AG (1CG) stock double in coming yearsJuly 2025 Catalysts & Community Consensus Stock Picks - newser.com
Can CRISPR Therapeutics AG (1CG) stock deliver double digit returnsJuly 2025 Closing Moves & Momentum Based Trading Signals - newser.com
Applying Wyckoff theory to CRISPR Therapeutics AG stock2025 EndofYear Setup & Growth Focused Stock Pick Reports - newser.com
Key resistance and support levels for CRISPR Therapeutics AG2025 Market Sentiment & Community Consensus Trade Alerts - newser.com
How big funds are accumulating CRISPR Therapeutics AG (1CG) stock2025 Volume Leaders & Accurate Technical Buy Alerts - newser.com
Why CRISPR Therapeutics AG (1CG) stock is listed among top recommendationsQuarterly Trade Report & Smart Swing Trading Techniques - newser.com
Will CRISPR Therapeutics AG (1CG) stock gain from green policies2025 Market Trends & Technical Confirmation Trade Alerts - newser.com
What valuation multiples suggest for CRISPR Therapeutics AG stock2025 Buyback Activity & Safe Capital Growth Stock Tips - newser.com
Is CRISPR Therapeutics AG stock cheap compared to fundamentalsMarket Trend Summary & Daily Oversold Stock Bounce Ideas - newser.com
Y Intercept Hong Kong Ltd Makes New $1.91 Million Investment in CRISPR Therapeutics AG $CRSP - MarketBeat
Wealthfront Advisers LLC Acquires Shares of 6,003 CRISPR Therapeutics AG $CRSP - MarketBeat
Is CRISPR Therapeutics AG stock a buy for dividend growthJuly 2025 Rallies & Low Drawdown Investment Strategies - newser.com
Is CRISPR Therapeutics AG stock a top pick in earnings seasonJuly 2025 Gainers & Comprehensive Market Scan Reports - newser.com
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
CRISPR Therapeutics (CRSP) Gains as FDA Eases Approval Pathway - GuruFocus
Gene editing therapy companies rise on word of streamlined FDA approval process - Seeking Alpha
FDA to Expedite Gene-Editing Approval Process, Impacting CRSP - GuruFocus
FDA Clears Way for Faster Personalized Gene Editing Therapy - Bloomberg.com
Key metrics from CRISPR Therapeutics AG’s quarterly dataWeekly Trend Report & AI Forecasted Stock Moves - newser.com
Visual analytics tools that track CRISPR Therapeutics AG performanceQuarterly Earnings Report & Expert Approved Momentum Trade Ideas - newser.com
Assessing CRISPR Therapeutics After First US Gene-Editing Therapy Spurs 47.5% Stock Surge - Sahm
Building trade automation scripts for CRISPR Therapeutics AG2025 Market WrapUp & Weekly High Return Stock Forecasts - newser.com
Finanzdaten der Crispr Therapeutics Ag-Aktie (CRSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):